Information for investors and
2023 Full-year results
Annual General Meeting 2024
Ad-hoc releases pursuant to art. 53 LR.
All necessary financial information of the company at a glance.
Medartis relies on efficient cooperation between the Board of Directors and the company management. We respect the interests of our shareholders and rely on clear rules in addition to open, transparent corporate communication.
|NAME||POSITION||COMMITTEE MEMBERSHIP||FIRST ELECTED||END CURRENT PERIOD|
|Dr. h.c. Thomas Straumann||Vice Chairman||Member of the SIC||1998||2024||+|
|Willi Miesch||Member of the Board||Chairman of the SIC||2010||2024||+|
|Nadia Tarolli Schmidt||Member of the Board||Chairman of the FAC||2022||2024||+|
|Dr. med. Daniel B. Herren||Member of the Board||Member of the HRCC|
Member of the SIC
|Ciro Roemer||Member of the Board||Member of the SIC|
Member of the FAC
|Damien Tappy||Member of the Board||Chairman of the HRCC|
Member of the FAC
HRCC = Human Resources and Compensation Committee | FAC = Finance and Audit Committee | SIC = Strategy and Innovation Committee
The following analysts evaluate the performance of Medartis stock and the investment opportunities for investors.
Stifel Nicolaus Europe Limited
Dylan Van Haaften
EC2V 6ET London
Mr Edouard Riva
Bryan Garnier & Co.
Mr. Alex Cogut
16 Old Queen Street
London SW1H 9HP
Frau Sandra Dietschy
Research Partners AG
Would you like to be informed about Medartis at first hand? Register and receive our news in electronic form.
Head of Corporate Communications
Corporate affairs, investor and media inquiries
Phone switchboard +41 (0)61 633 34 34
Phone direct +41 79 392 80 32
Corporate Communications Manager
Media inquiries, corporate publishing and internal communication
Right side of the the picture
Phone direct +41 (0)61 633 37 34